Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management

K. A. Schulman, B. Kinosian, T. A. Jacobson, H. Glick, M. K. Willian, H. Koffer and J. M. Eisenberg
Department of Medicine, Robert Wood Johnson Foundation Clinical Scholars Program, University of Pennsylvania, Philadelphia.

We performed a cost-effectiveness analysis of pharmacologic treatment of high blood cholesterol levels. Agents modeled were cholestyramine, colestipol, gemfibrozil, lovastatin, niacin, and probucol. Pharmacologic effectiveness was estimated from reported studies. Cost estimates reflect societal resource consumption. Annual costs for therapy ranged from $327 (niacin) to $1881 (lovastatin, 80 mg/d). Niacin was the most efficient agent for reducing low-density lipoprotein cholesterol levels, having an average cost over 5 years of $139 per percent reduction in low-density lipoprotein cholesterol level. Lovastatin (20 mg/d) was also efficient ($177 per percent reduction). Cholestyramine was least efficient at $347. For high-density lipoprotein cholesterol, niacin was most efficient, at $116 per percent increase in high-density lipoprotein cholesterol level, followed by gemfibrozil at $271. Analyses combining low-density lipoprotein cholesterol and high-density lipoprotein cholesterol effects suggest that niacin and lovastatin (20 mg/d) were most efficient for reducing cardiovascular risk.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cost effectiveness of statins in coronary heart disease
Franco et al.
J. Epidemiol. Community Health 2005;59:927-933.
ABSTRACT | FULL TEXT  

Cost-effectiveness Implications of the Timing of Antiretroviral Therapy in HIV-Infected Adults
Schackman et al.
Arch Intern Med 2002;162:2478-2486.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Cholesterol-Lowering Therapies according to Selected Patient Characteristics
Prosser et al.
ANN INTERN MED 2000;132:769-779.
ABSTRACT | FULL TEXT  

New Molecular Targets for Cholesterol-Lowering Therapy
Izzat et al.
J. Pharmacol. Exp. Ther. 2000;293:315-320.
ABSTRACT | FULL TEXT  

Experimental versus Observational Data in the Economic Evaluation of Pharmaceuticals
Drummond
Med Decis Making 1998;18:S12-S18.
 

Treating Hyperlipidemia for the Primary Prevention of Coronary Disease: Are Higher Dosages of Lovastatin Cost-effective?
Perreault et al.
Arch Intern Med 1998;158:375-381.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Populationwide Educational Approaches to Reduce Serum Cholesterol Levels
Tosteson et al.
Circulation 1997;95:24-30.
ABSTRACT | FULL TEXT  

Discontinuation of Antihyperlipidemic Drugs -- Do Rates Reported in Clinical Trials Reflect Rates in Primary Care Settings?
Andrade et al.
NEJM 1995;332:1125-1131.
ABSTRACT | FULL TEXT  

Selection of End Points in Economic Evaluations of Coronary-heart-disease Interventions
Drummond et al.
Med Decis Making 1993;13:184-190.
ABSTRACT